Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
P/B ratio for Minerva Surgical, Inc. (UTRS)
P/B ratio as of 2022: 0.37
According to Minerva Surgical, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.37. At the end of 2021 the company had a P/B ratio of 0.82.
P/B ratio history for Minerva Surgical, Inc. from 2019 to 2022
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2022 | 0.37 |
| 2021 | 0.82 |
| 2020 | -0.83 |
| 2019 | -0.82 |